The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
Crossref DOI link: https://doi.org/10.1007/s40487-020-00133-1
Published Online: 2020-12-17
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Goldschmidt, Jerome
Hanes, Vladimir
Funding for this research was provided by:
Amgen
Text and Data Mining valid from 2020-12-17
Version of Record valid from 2020-12-17
Article History
Received: 30 September 2020
Accepted: 24 October 2020
First Online: 17 December 2020